|
Vaginal cancer is usually a squamous cell carcinoma, most often occurring in women > 60. The most common symptom is abnormal vaginal bleeding. Diagnosis is by biopsy. Treatment for many small localized cancers is hysterectomy plus vaginectomy and lymph node dissection; for most others, radiation therapy is used.
Vaginal cancer accounts for 1% of gynecologic cancers in the US. Average age at diagnosis is 60 to 65. Risk factors include human papillomavirus infection and cervical or vulvar cancer. Exposure to diethylstilbestrol in utero predisposes to clear cell adenocarcinoma of the vagina, which is rare; mean age at diagnosis is 19.
Most (95%) primary vaginal cancers are squamous cell carcinomas; others include primary and secondary adenocarcinomas, secondary squamous cell carcinomas (in older women), clear cell adenocarcinomas (in young women), and melanomas. The most common vaginal sarcoma is sarcoma botryoides (embryonal rhabdomyosarcoma); peak incidence is at age 3.
Most vaginal cancers occur in the upper third of the posterior vaginal wall. They may spread by direct extension (into the local paravaginal tissues, bladder, or rectum), through inguinal lymph nodes from lesions in the lower vagina, through pelvic lymph nodes from lesions in the upper vagina, or hematogenously.
Symptoms and Signs
Most patients present with abnormal vaginal bleeding: postmenopausal, postcoital, or intermenstrual. Some also present with a watery vaginal discharge or dyspareunia. A few patients are asymptomatic, and the lesion is discovered during routine pelvic examination or evaluation of an abnormal Papanicolaou (Pap) test. Vesicovaginal or rectovaginal fistulas are manifestations of advanced disease.
Diagnosis
Punch biopsy is usually diagnostic, but wide local excision is occasionally necessary. Cancers are staged clinically (see Table 8: Gynecologic Tumors: Vaginal Cancer by Stage ), based primarily on physical examination, endoscopy (ie, cystoscopy, proctoscopy), chest x-ray (for pulmonary metastases), and usually CT (for abdominal or pelvic metastases). Survival rates depend on the stage.
|
Table 8
|
PrintOpen table  |
 | | |
| Vaginal Cancer by Stage |
|
Stage
|
Description
|
5-yr Survival Rate*
|
|
I
|
Limited to the vaginal wall
|
65−70%
|
|
II
|
Invading subvaginal tissues
|
47%
|
|
III
|
Extending to the pelvic wall
|
30%
|
|
IV
|
Extending beyond the true pelvis or involving the bladder or rectal mucosa
|
15−20%
|
|
*Prognosis is worse if the primary tumor is large or poorly differentiated.
|
|
Treatment
Stage I tumors within the upper third of the vagina can be treated with radical hysterectomy, upper vaginectomy, and pelvic lymph node dissection. Most other primary tumors are treated with radiation therapy, usually a combination of external beam radiation therapy and brachytherapy. If radiation therapy is contraindicated because of vesicovaginal or rectovaginal fistulas, pelvic exenteration is done.
Last full review/revision November 2008 by David M. Gershenson, MD; Pedro T. Ramirez, MD
|
